TAK vs. WST: Takeda Pharmaceutical vs. West Pharmaceutical Services Stock Comparison

Company Profile

Takeda Pharmaceutical (TAK) and West Pharmaceutical Services (WST) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but TAK is classified in Pharmaceuticals while WST is classified in Life Sciences Tools & Services.

West Pharmaceutical Services (WST) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. West Pharmaceutical Services (WST) has a non-negative beta of 1.13.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

West Pharmaceutical Services (WST) at 21.23% sits in the top ROE quartile, while Takeda Pharmaceutical (TAK) at 0.56% is closer to the peer norm — stronger capital efficiency for WST.

West Pharmaceutical Services (WST) at 18.81% converts revenue to bottom-line profit above its industry’s benchmark range, while Takeda Pharmaceutical (TAK) at 0.87% keeps roughly the typical share for its industry.

Both Takeda Pharmaceutical (TAK) at 24.55% and West Pharmaceutical Services (WST) at 25.37% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

West Pharmaceutical Services (WST) at 6.25% is around its peer norm for revenue growth, while Takeda Pharmaceutical (TAK) at -1.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Takeda Pharmaceutical (TAK) at 77.96% sits in the top EPS growth quartile, while West Pharmaceutical Services (WST) at 1.49% is closer to the peer norm — faster per-share earnings growth for TAK.

Growth Metrics

Financial Strength

West Pharmaceutical Services (WST) at 2.82 keeps current ratio within its industry’s typical mid-range, while Takeda Pharmaceutical (TAK) at 1.15 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TAK.

West Pharmaceutical Services (WST) at 0.11 carries an industry-typical debt-to-equity mix, while Takeda Pharmaceutical (TAK) at 0.72 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Both Takeda Pharmaceutical (TAK) at 953.28% and West Pharmaceutical Services (WST) at 0.22% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile West Pharmaceutical Services (WST) reports 9.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both look expensive on trailing earnings: West Pharmaceutical Services (WST) at 44.87 sits in the richer P/E ratio quartile, and Takeda Pharmaceutical (TAK) at 300.29 is richer still, above its industry range.

Takeda Pharmaceutical (TAK) at 0.01 sits in the cheaper P/S ratio quartile while West Pharmaceutical Services (WST) at 8.20 prices around its industry’s middle — TAK costs less per dollar of sales, though read it alongside growth and margins.

Takeda Pharmaceutical (TAK) at 1.43 looks cheap against book in the lower P/B ratio quartile, while West Pharmaceutical Services (WST) at 9.40 carries a premium in the upper quartile — a clear price-to-book gap.

Valuation Metrics